Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
NCT07108244 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43
Last updated 2025-12-19
Summary
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production. Bilateral inferior petrosal sinus sampling (IPSS) is the gold standard for this distinction, with a diagnostic accuracy of 98%. However, IPSS is an invasive procedure and an indi-rect diagnostic method, rarely providing reliable data on the exact location of the PitNET. This has a major impact on the therapeutic approach, short and long-term remission rates, and other outcomes. Hybrid Positron-emission tomography-Magnetic Resonance Imaging (PET-MRI) using O-(2-\[18F\]-fluo-roethyl)-L-tyrosine (\[18F\]FET) is promising in this respect. Recent data published by our research group demonstrate a a sensitivity of 100% a high accuracy in in the precise localization of ACTH-secreting PitNETs. We hypothesize that \[18F\]FET PET-MRI could become the new non-invasive diagnostic stand-ard, but data regarding a direct comparison between the diagnostic impact of \[18F\]FET PET-MRI versus IPSS in the differentiation between CD and ectopic CS are lacking. In addition, there are currently no other reliable biomarkers to distinguish the two disorders. The investigators hypothesize that the ACTH-dependent biomarker copeptin could be a valuable addition in this regard. The aim of this prospective diagnostic study is to compare the diagnostic accuracy of \[18F\]FET-PET-MRI and IPSS in differentiating CD from ectopic CS in patients with ACTH-dependent hypercortisolism.
Conditions
- Cushing Disease
Interventions
- DIAGNOSTIC_TEST
-
[18F]FET PET-MRI
All participants will undergo both \[18F\]fluoroethyltyrosine positron emission tomography-magnetic resonance imaging (\[18F\]FET-PET-MRI) and inferior petrosal sinus sampling (IPSS) as part of the diagnostic work-up for ACTH-dependent hypercortisolism. The purpose is to compare the diagnostic accuracy of these two modalities in distinguishing Cushing's disease from ectopic ACTH secretion. The results from both diagnostic tests will be communicated to the treating medical team and the participant to guide further clinical management.
Sponsors & Collaborators
- collaborator OTHER
-
University Hospital, Basel, Switzerland
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-22
- Primary Completion
- 2029-07-30
- Completion
- 2029-07-30
Countries
- Netherlands
- Switzerland
Study Locations
More Related Trials
-
Multicenter Pheochromocytoma and Paraganglioma Evaluation
NCT03344016 ·Status: RECRUITING ·Phase: NA
-
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
NCT03714763 ·Status: UNKNOWN ·Phase: NA
-
Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
NCT06635993 ·Status: RECRUITING
-
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
NCT02539433 ·Status: COMPLETED ·Phase: NA
-
Validation of [18F]FES for Imaging of Brain Estrogen Receptors
NCT01842217 ·Status: TERMINATED ·Phase: NA
-
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
NCT06480721 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
18F-FET PET in Childhood Brain Tumours
NCT03216148 ·Status: UNKNOWN ·Phase: PHASE2
-
A Comparison of Static and Dynamic PET/CT (HYPOTHESIS Generation Study)
NCT05110443 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network
NCT07203495 ·Status: ACTIVE_NOT_RECRUITING
-
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
NCT07238322 ·Status: COMPLETED
-
The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy
NCT01248000 ·Status: COMPLETED
-
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
NCT07274397 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessment of Investigational Positron Emission Tomography and Post-Processing Procedures Performed as Add-ons to Standard of Care Imaging
NCT03490812 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
NCT03042416 ·Status: COMPLETED ·Phase: PHASE3
-
18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma
NCT04001257 ·Status: COMPLETED
-
Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia
NCT02010957 ·Status: TERMINATED ·Phase: PHASE3
-
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT06795113 ·Status: RECRUITING
-
18FDG PET Textural Indices in Adrenal Lesion
NCT03469102 ·Status: COMPLETED
-
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities
NCT04315584 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
NCT00068146 ·Status: COMPLETED
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
NCT02186678 ·Status: COMPLETED ·Phase: NA
-
First-in-human Evaluation of [18F]CETO
NCT05361083 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
NCT05636540 ·Status: RECRUITING ·Phase: EARLY_PHASE1